Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 501–600 of 1,001
Sarafidis, P. A., Pella, E., Kanbay, M., & Papagianni, A. A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220825121304 · Cited by 24
Guo, W., Li, H., Li, Y., & Kong, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115025 · Cited by 23
Afghahi, H., Svensson, M. K. E., Pirouzifard, M., Eliasson, B., & Svensson, A. (2015) · Diabetologia · doi:10.1007/s00125-015-3548-1 · Cited by 21
Petrák, O., Zelinka, T., Štrauch, B., Rosa, J., Šomlóová, Z., Indra, T., Turková, H., Holaj, R., & Widimsky, J., Jr. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2015.24 · Cited by 23
Novel avenues for drug discovery in diabetic kidney disease
Breyer, M. D., & Kretzler, M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1398731 · Cited by 21
Haas, M. J., Jurado-Flores, M., Hammoud, R., Feng, V., Gonzales, K., Onstead‐Haas, L., & Mooradian, A. D. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000648 · Cited by 21
Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor β2 Agonist
Trasino, S. E., Tang, X., Shevchuk, M. M., Choi, M. E., & Gudas, L. J. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.249375 · Cited by 21
Nakhoul, N., Thawko, T., Farber, E., Dahan, I., Tadmor, H., Nakhoul, R., Hanut, A., Salameh, G., Shagrawy, I., & Nakhoul, F. M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7907605 · Cited by 22
An, J., Niu, F., & Sim, J. J. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2633 · Cited by 21
Palmer, S. C., Ruospo, M., Teixeira-Pinto, A. M., Craig, J. C., Macaskill, P., & Strippoli, G. F. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.011 · Cited by 22
Pochopień, M., Cherney, D. Z. I., Folkerts, K., Lévy, P., Millier, A., Morris, S., Roy-Chaudhury, P., Sullivan, S. D., & Mernagh, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88808 · Cited by 21
Wish, J. B., & Pérgola, P. E. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.09.002 · Cited by 24
Urinary Biomarkers of Tubular Health and Risk for Kidney Function Decline or Mortality in Diabetes
Chen, T. K., Coca, S. G., Thiessen‐Philbrook, H., Heerspink, H. J. L., Obeid, W., Ix, J. H., Fried, L. F., Bonventre, J. V., El-Khoury, J. M., Shlipak, M. G., et al. (2022) · American Journal of Nephrology · doi:10.1159/000528918 · Cited by 20
Self-citationUse of ACEi/ARBs, SGLT2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD
Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae014 · Cited by 24
mTOR pathway: A key player in diabetic nephropathy progression and therapeutic targets
Shi, J., Liu, X., Jiao, Y., Tian, J., An, J., Zou, G., & Zhuo, L. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101260 · Cited by 30
Heerspink, H. J. L., Oberbauer, R. W., Perco, P., Heinzel, A., Heinze, G., Mayer, G. J., & Mayer, B. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv210 · Cited by 20
Wong, M. Y. W., Saad, S., Zhang, J., Gross, S., Jarolimek, W., Schilter, H. C., Chen, J., Gill, A. J., Pollock, C. A., & Wong, M. G. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00698.2013 · Cited by 20
Self-citationAntihypertensive treatment and renal protection: Is there a J‐curve relationship?
Viazzi, F. C., Leoncini, G., Grassi, G. M., & Pontremoli, R. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13396 · Cited by 20
de Zeeuw, D., & Heerspink, H. J. L. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa013 · Cited by 20
Scholtes, R. A., van Baar, M. J. B., Kok, M. D., Bjornstad, P., Cherney, D. Z. I., Joles, J. A., & van Raalte, D. H. (2021) · Nephrology · doi:10.1111/nep.13839 · Cited by 20
Morales, E., Gutiérrez, E., Caro, J., Sevillano, Á., Rojas-Rivera, J. E., & Praga, M. (2015) · Nefrología · doi:10.1016/j.nefro.2015.09.008 · Cited by 20
SGLT2 inhibitors in non-diabetic kidney disease
Tesař, V. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/145734 · Cited by 21
Long‐term case study of a Wuzhishan miniature pig with diabetes
Niu, M., Liu, Y., Xiang, L., Zhao, Y., Yuan, J., Jia, Y., Dai, X., & Chen, H. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12098 · Cited by 20
Brunström, M., & Carlberg, B. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026686 · Cited by 19
Edmonston, D. L., South, A. M., Sparks, M. A., & Cohen, J. B. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2020.07.002 · Cited by 22
Donate‐Correa, J., Sánchez-Niño, M. D., González-Luis, A., Ferri, C. M., Martín-Olivera, A., Martín‐Núñez, E., Fernández‐Fernández, B., Tagua, V. G., Fernández, C. M., Ortíz, A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac143 · Cited by 20
Sugawara, H., Moniwa, N., Kuno, A., Ohwada, W., Osanami, A., Shibata, S., Kimura, Y., Abe, K., Gocho, Y., Tanno, M., et al. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.12.001 · Cited by 19
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Fecal microbiota transplantation is a promising therapy for kidney diseases
Zhang, J., Ren, X., Li, B., Zhao, Z., Li, S., & Zhai, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1628722 · Cited by 20
Self-citationBouby, N., Clark, W. F., Roussel, R., Taveau, C., & Wang, C. J. (2014) · Obesity Facts · doi:10.1159/000360889 · Cited by 20
Singh, V. K., Mishra, A., Gupta, K., Misra, R., Patel, M. L., & Shilpa, K. (2015) · Indian Journal of Nephrology · doi:10.4103/0971-4065.151764 · Cited by 59
Huang, R., Feng, Y., Wang, Y., Qin, X., Melgiri, N. D., Sun, Y., & Li, X. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168582 · Cited by 18
Calpain-10 drives podocyte apoptosis and renal injury in diabetic nephropathy
Wang, T., Gao, Y., Wang, X., Shi, Y., Xu, J., Wu, B., He, J., & Li, Y. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s217924 · Cited by 18
Jin, D., Huang, W., Meng, X., Yang, F., Bao, Q. D., Zhang, M., Yang, Y., Ni, Q., Lian, F., & Tong, X. (2019) · Trials · doi:10.1186/s13063-019-3821-6 · Cited by 21
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Leehey, D. J. (2020) · Kidney360 · doi:10.34067/kid.0001252019 · Cited by 19
Self-citationBhailis, A. M. D., Azmi, S., & Kalra, P. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211020664 · Cited by 21
L-NAME Administration Enhances Diabetic Kidney Disease Development in an STZ/NAD Rat Model
Corremans, R., D’Haese, P. C., Vervaet, B. A., & Verhulst, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312767 · Cited by 18
Ruiz‐Hurtado, G., & Ruilope, L. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvu023 · Cited by 19
Achieving remission of proteinuria in childhood CKD
Ruggenenti, P. L., Cravedi, P., Chianca, A., Caruso, R., & Remuzzi, G. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3495-1 · Cited by 18
Sedláková, L., Chábová, V. Č., Doleželová, Š., Škaroupková, P., Kopkan, L., Husková, Z., Červenková, L., Kikerlová, S., Vaněčková, I., Sadowski, J., et al. (2017) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2016.1235184 · Cited by 19
Lin, C., Wu, Y.-T., Yang, W.-C., Tsai, M.-J., Liu, J., Yang, C., Li, S., Ou, S., Tarng, D., & Hsu, C.-C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189126 · Cited by 18
Change in albuminuria as a surrogate endpoint
Waijer, S. W., Gansevoort, R. T., & Heerspink, H. J. L. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000541 · Cited by 18
Change in albuminuria as a surrogate endpoint in chronic kidney disease – Authors' reply
Heerspink, H. J. L., Coresh, J., Gansevoort, R. T., & Inker, L. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30080-4 · Cited by 18
Diabetic Nephropathy and Diabetic Kidney Disease
Suneja, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115029 · Cited by 23
Zhao, M., Wang, R., Yu, Y., Chang, M., Ma, S., Zhang, H., Qu, H., & Zhang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638611 · Cited by 22
Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts
Márquez, D. F., Rodríguez‐Sánchez, E., Segura, J., Ruilope, L. M., & Ruiz‐Hurtado, G. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.10.008 · Cited by 21
Novel effective drugs for diabetic kidney disease? or not?
Gentile, G., Mastroluca, D., Ruggenenti, P. L., & Remuzzi, G. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.979151 · Cited by 18
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 18
Latin American recommendations for the management of hypertension in adults (RELAHTA 2)
Sabio, R., Valdez, P. R., Abuabara-Turbay, Y., Belgeri, R. E. A., de Morvil, G. A. A. O., Arias, C., Cámera, L. A., Carballo-Zárate, V., Falcón, H. C., Chahin, R. C., et al. (2019) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2019.06(01)86-123 · Cited by 22
Yang, X., Hu, C., Wang, S., & Chen, Q. (2020) · Medicine · doi:10.1097/md.0000000000020678 · Cited by 17
Sridhar, V. S., Liu, H., & Cherney, D. Z. I. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.02.324 · Cited by 19
Shelke, V., Dagar, N., & Gaikwad, A. B. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122095 · Cited by 16
Arici, M., ALTUN, B., Araz, M., Atmaca, A. A., Demir, T., Ecder, T., Güz, G., Yavuz, D. G., Yildiz, A., & Yilmaz, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384454 · Cited by 19
Recent advances in treatment of heart failure
Kitai, T., & Tang, W. H. W. (2015) · F1000Research · doi:10.12688/f1000research.7022.1 · Cited by 18
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease
Pena-Polanco, J. E., & Fried, L. F. (2016) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.05.009 · Cited by 16
Self-citationWang, M., Wang, Z., Zhou, J., Sun, W., Wang, Y., Han, M., Yang, H., Liu, W. J., & Wang, Y. (2018) · Trials · doi:10.1186/s13063-018-2749-6 · Cited by 21
Representing the KNOW-CKD Investigators Group, Kim, H., Park, S., Jhee, J. H., Yun, H.-R., Park, J. T., Han, S. H., Lee, J., Kim, S. W., Kim, Y. H., et al. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1292-3 · Cited by 16
Cao, X., Wei, R., Zhou, J. F., Zhang, X., Gong, W., Jin, T., & Chen, X. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2598-1 · Cited by 16
McCoy, I. E., Han, J., Montez‐Rath, M. E., Chertow, G. M., & Rhee, J. J. (2020) · Clinical Diabetes · doi:10.2337/cd19-0087 · Cited by 17
Shenoy, S. V., Nagaraju, S. P., Bhojaraja, M. V., Prabhu, R., Rangaswamy, D., & Rao, I. R. (2021) · Nephrology · doi:10.1111/nep.13917 · Cited by 18
Yanai, K., Ishibashi, K., & Morishita, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662544 · Cited by 17
de Sá, J. R., Rangel, É. B., Canani, L. H. S., Bauer, A. C., Escott, G. M., Zelmanovitz, T., Bertoluci, M. C., & Silveiro, S. P. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00843-8 · Cited by 23
New data do not SUPPORT triple RAAS blockade
Danser, A. H. J., & van den Meiracker, A. H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.30 · Cited by 16
Luo, Y. L., Lü, K., Liu, G., Wang, J., Laurent, I., & Zhou, X. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0707-4 · Cited by 18
Wang, D.-Q., Miao, X., Gao, J. X., Zhou, Y., Ji, F., & Cheng, X. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.04.014 · Cited by 16
FHL2 mediates podocyte Rac1 activation and foot process effacement in hypertensive nephropathy
Li, S., Chu, P., Huang, P., Hsieh, T., Suszták, K., & Tarng, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-42328-1 · Cited by 16
Kim, H., Park, J., Nam, K. H., Jhee, J. H., Yun, H., Park, J. T., Han, S. H., Chung, W., Oh, K., Park, S. K., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy403 · Cited by 18
Serum Potassium and Cardiovascular Outcomes: The Highs and the Lows
Toto, R. D. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00030117 · Cited by 16
Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Speeckaert, R., Delrue, C., & Speeckaert, M. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030921 · Cited by 17
Zimering, M. B. (2017) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/4/4/00184 · Cited by 19
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 18
Aliyu, M. H., Wudil, U. J., Ingles, D. J., Shepherd, B. E., Gong, W., Musa, B. M., Hamza, M., Sani, M. U., Abdu, A., Nalado, A. M., et al. (2019) · Trials · doi:10.1186/s13063-019-3436-y · Cited by 16
Treatment strategies for hypertension in patients with type 1 diabetes
Katsimardou, A., Imprialos, K. P., Stavropoulos, K., Sachinidis, A. G., Doumas, M. N., & Athyros, V. G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729124 · Cited by 17
Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
Erraez, S., López-Mesa, M., & Gómez-Fernández, P. (2020) · Nefrología · doi:10.1016/j.nefro.2020.10.001 · Cited by 17
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis
Barbosa, C. V., Lang, H., Melk, A., & Schmidt, B. M. W. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac001 · Cited by 18
Deng, X., Li, D., Tang, Q., & Chen, Y. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/6962654 · Cited by 16
Zou, X., Zhang, X., Liu, X., Li, R., Wang, M., Wu, W., Sui, Y., & Zhao, H. (2015) · Journal of Diabetes Research · doi:10.1155/2015/310645 · Cited by 15
Does cardiovascular protection translate into renal protection?
Ruiz‐Hurtado, G., & Ruilope, L. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.97 · Cited by 16
Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus
Joven, M. H., & Anderson, R. J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0613-6 · Cited by 18
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Bhanot, S., & Leehey, D. J. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0612-7 · Cited by 15
Self-citationCoppenrath, V. A., Filosa, L. A., Akselrod, E., & Carey, K. M. (2017) · American Journal of Pharmaceutical Education · doi:10.5688/ajpe816106 · Cited by 15
Ikeme, J. C., Pergola, P. E., Scherzer, R., Shlipak, M. G., Catanese, L., McClure, L. A., Benavente, O. R., & Peralta, C. A. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010091 · Cited by 14
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 18
Schuster, A., Al-Makki, A. A., & Shepler, B. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.09.009 · Cited by 15
15th ISoP Annual Meeting “Cubism in Pharmacovigilance” Prague, Czech Republic 27-30 October, 2015
Mantarro, S., Rossi, M., Blandizzi, C., Capogrosso-Sansone, A., Convertino, I., Montagnani, S., Marino, A., Saporiti, A., Garibaldi, D., D'Amico, R., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0346-0 · Cited by 15
Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
Ghosal, S., & Sinha, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1114894 · Cited by 15
Sourij, H., Aberer, F., Antlanger, M., Brix, J., Cejka, D., Clodi, M., Edlinger, R., Eller, K., Horn, S., Kaser, S., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0992-y · Cited by 14
Ziff, O. J., Covic, A. C., & Goldsmith, D. J. A. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12803 · Cited by 14
Coca, A., López-Jaramillo, P. A., Thomopoulos, C., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001593 · Cited by 18
Xing-hua, L. I. U., Ma, L., & Li, Z. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01179-8 · Cited by 17
de Sá, J. R., Rangel², É. B., Bauer, A. C., Betônico, C. D. C. R., Zelmanovitz, T., Moura, A. F. D. S., Silveiro, S. P., Canani, L. H. S., Lauria, M. W., Lamounier, R. N., et al. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-18 · Cited by 18
Stem cell-derived exosomal MicroRNAs: Potential therapies in diabetic kidney disease
Wang, H., Wang, J., Liu, T., Leng, Y., & Yang, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114961 · Cited by 14
New molecular insights in diabetic nephropathy
Checheriţă, I. A., Manda, G., Hinescu, M. E., Peride, I., Niculae, A., Bilhă, Ş., Grămăticu, A., Voroneanu, L. E., & Covic, A. C. (2016) · International Urology and Nephrology · doi:10.1007/s11255-015-1203-x · Cited by 15
Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
Goldenberg, R., Berall, M. J., Chan, C. T., Cherney, D. Z. I., Lovshin, J. A., McFarlane, P. A., Senior, P. A., Verma, S., & Weinstein, J. J. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.008 · Cited by 17
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease
Provenzano, M., Andreucci, M., Garofalo, C., Minutolo, R., Serra, R., & Nicola, L. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1869720 · Cited by 14
Physiology and Regulation of the Renin–Angiotensin–Aldosterone System
Carey, R. M., & Padia, S. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00001-5 · Cited by 20
Kuang, L., You, Y., Qi, J., Chen, J., Zhou, X., Ji, S., Cheng, J., Kwan, H. Y., Jiang, P., Sun, X., et al. (2024) · Environmental Toxicology · doi:10.1002/tox.24179 · Cited by 13
Xu, X., Shen, S., Dong, Y., Jiang, L., Wang, J., & Shao, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156385 · Cited by 14
The distal nephron biomarkers associate with diabetic kidney disease progression
Tamargo, C. L., Coca, S. G., Thiessen‐Philbrook, H., Hu, D. G., Ix, J. H., Shlipak, M. G., Fried, L. F., Gutiérrez, O. M., Waikar, S. S., Schrauben, S. J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.186836 · Cited by 13
Self-citationPrimary Care of the Patient with Chronic Kidney Disease
Kiefer, M. M., & Ryan, M. J. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.05.003 · Cited by 18
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.